According to Iconovo, the Chinese Patent Office has said it will approve the company’s application for a patent covering its ICOres reservoir-based dry powder inhaler platform that will provide protection until 2040. The ICOres platform has already received patent protection in the US, Europe, Sweden, India, and Japan, the company said.
The dual chamber ICOres device has already been used in several DPI projects, including a generic version of Symbicort developed by Amneal.
Iconovo VP of Business Development Roger Lassing commented, “The preliminary notification from the Chinese Patent Office strengthens our intellectual property rights in China and enhances the value of our product portfolio. China is a fast-growing market and already one of the largest pharmaceutical markets in the world. Reservoir inhalers are of particular interest in China where Turbuhaler from AstraZeneca is successful and inhalers with many doses are popular.”
Read the Iconovo press release.
